Earnings Feed
Start Free
Home/Filings/4/0000914190-09-000569
4//SEC Filing

KASH PETER M 4

Accession 0000914190-09-000569

CIK 0001133869other
View on SEC.govCompany Profile

Filed

Jul 8, 8:00 PM ET

Accepted

Jul 9, 5:46 PM ET

Size

17.9 KB

Accession

0000914190-09-000569

Insider Transaction Report

Form 4
Period: 2009-07-07
Nile Therapeutics, Inc.NLTX
KASH PETER M
Director
Transactions
  • Purchase

    Warrant (Right to Buy)

    2009-07-07+24,703→ 24,703 total
    Exercise: $1.71From: 2009-07-07Exp: 2014-07-07→ Common Stock (24,703 underlying)
  • Purchase

    Warrant (Right to Buy)

    2009-07-07+24,704→ 24,704 total
    Exercise: $1.25From: 2009-07-07Exp: 2014-07-07→ Common Stock (24,704 underlying)
  • Purchase

    Warrant (Right to Buy)

    2009-07-07+49,407→ 49,407 total
    Exercise: $2.28From: 2009-07-07Exp: 2014-07-07→ Common Stock (49,407 underlying)
  • Purchase

    Common Stock

    2009-07-07+98,814→ 1,596,208 total
Holdings

  • Warrant (Right to Buy)

    Exercise: $2.71From: 2007-09-17Exp: 2011-09-17→ Common Stock (1,052 underlying)
    1,052

  • Common Stock

    (indirect: By Spouse)
    496,589

  • Common Stock

    (indirect: By Foundation)
    165,530

  • Stock Option (Right to Buy)

    Exercise: $4.50Exp: 2018-01-25→ Common Stock (60,000 underlying)
    60,000

  • Stock Option (Right to Buy)

    Exercise: $0.93From: 2010-01-01Exp: 2018-12-22→ Common Stock (35,000 underlying)
    35,000
Footnotes (4)
  • [F1]The reported securities were part of a unit purchase by the Reporting Person at a price of $1.265 per unit, with each unit consisting of one share of common stock and one warrant to purchase common stock. 25% of the warrants are exercisable at $1.25 per share, an additional 25% are exercisable at $1.71 per share, and the remaining 50% are exercisable at $2.28 per share.
  • [F2]Total aggregate ownership previously underreported by 50 shares.
  • [F3]Held by the Reporting Person's spouse as custodian for the benefit of their minor children under the Uniform Gift to Minors Act. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of these shares for purposes of Section 16 or any other purpose.
  • [F4]The shares subject to the option vest in three equal installments on September 17, 2008, September 17, 2009, and September 2010.

Documents

1 file

Issuer

Nile Therapeutics, Inc.

CIK 0001133869

→
Entity typeother

Related Parties

1
  • filerCIK 0001253023

Filing Metadata

Form type
4
Filed
Jul 8, 8:00 PM ET
Accepted
Jul 9, 5:46 PM ET
Size
17.9 KB
View on SEC.gov